Foerster, Beat, Abufaraj, Mohammad, Mari, Andrea, Seisen, Thomas, Bandini, Marco, Schweitzer, Donald, Czech, Anna K., Moschini, Marco, D'Andrea, David, Bianchi, Marco, Hendricksen, Kees, Rouprêt, Morgan, Briganti, Alberto, van Rhijn, Bas W. G., Chłosta, Piotr, Colin, Pierre, John, Hubert, and Shariat, Shahrokh F.
In this multicenter observational study, we evaluated different tumor diameters for identifying ≥ pT2 upper tract urothelial carcinoma at radical nephroureterectomy. In preoperative predictive models including 932 patients, the > 2-cm cutoff (odds ratio, 2.38; 95% confidence interval, 1.70-3.32; P < .001) was independently associated. This tumor size threshold could help to best select patients for kidney-sparing surgery. Introduction: The objective of this study was to evaluate the performance of different tumor diameters for identifying ≥ pT2 upper tract urothelial carcinoma (UTUC) at radical nephroureterectomy. Patients and Methods: This was a multi-institutional retrospective study that included 932 patients who underwent radical nephroureterectomy for nonmetastatic UTUC between 2000 and 2016. Tumor sizes were pathologically assessed and categorized into 4 groups: ≤ 1 cm, 1.1 to 2 cm, 2.1 to 3 cm, and > 3 cm. We performed logistic regression and decision-curve analyses. Results: Overall, 45 (4.8%) patients had a tumor size ≤ 1 cm, 141 (15.1%) between 1.1 and 2 cm, 247 (26.5%) between 2.1 and 3 cm, and 499 (53.5%) > 3 cm. In preoperative predictive models that were adjusted for the effects of standard clinicopathologic features, tumor diameters > 2 cm (odds ratio, 2.38; 95% confidence interval, 1.70-3.32; P < .001) and > 3 cm (odds ratio, 1.81; 95% confidence interval, 1.38-2.38; P < .001) were independently associated with ≥ pT2 pathologic staging. The addition of the > 2-cm diameter cutoff improved the area under the curve of the model from 58.8% to 63.0%. Decision-curve analyses demonstrated a clinical net benefit of 0.09 and a net reduction of 8 per 100 patients. Conclusion: The 2-cm cutoff appears to be most useful in identifying patients at risk of harboring ≥ pT2 UTUC. This confirms the current European Association of Urology guideline's risk stratification. Tumor size alone is not sufficient for optimal risk stratification, rather a constellation of features is needed to select the best candidate for kidney-sparing surgery. [ABSTRACT FROM AUTHOR]